HENGRUI PHARMA (01276) has issued an announcement stating that recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company"), received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (hereinafter referred to as "NMPA") for SHR-1139 injection, and will soon commence clinical trials.
SHR-1139 injection is a dual-specific antibody independently developed by the Company that simultaneously targets IL-23p19 and IL-36R, blocking both pathways at once and potentially providing more comprehensive and durable inflammation control.
According to available information, no comparable drug has been approved for marketing either domestically or internationally to date. As of now, the cumulative R&D investment in SHR-1139 injection and related projects amounts to approximately RMB 162.70 million (unaudited).
Comments